Welcome to Markets Desk, here's what's moving the needle today.
Nvidia is pulling away from the broader market again, and analysts say the momentum has legs. The chipmaker more than doubled revenue year over year and is projecting roughly seventy percent growth heading into fiscal year two thousand twenty eight. When a company that size is still compounding at that rate, the market tends to price in more runway, not less.
Shifting from silicon to tunnels, The Boring Company just closed a three billion dollar raise at a twenty-three billion dollar valuation. Elon Musk's infrastructure venture is drawing serious institutional appetite, largely on the coattails of SpaceX's anticipated public offering. Investors are betting that proximity to Musk's broader empire carries its own premium, though that valuation demands execution at scale.
And in biotech, Viking Therapeutics is in phase three trials for its weight-loss drug candidate, with analysts posting a ninety-two dollar price target on the stock. Getting there requires clean trial data, a clear regulatory path, and a commercial launch that can compete in an increasingly crowded GLP-one space. The upside is real, but so is the distance between here and there.
That's the tape. Markets Desk, signing off the floor.
